Roth Capital Downgrades Tonix Pharma (TNXP) to Neutral Citing PTSD Setback
Tweet
Share
E-mailGet Alerts TNXP Hot Sheet
Price: $11.95 -0.08%
Rating Summary:
5 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 4 | Down: 7 | New: 31
Rating Summary:
5 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 4 | Down: 7 | New: 31
Join SI Premium – FREE
Roth Capital downgraded Tonix Pharma (NASDAQ: TNXP) from Buy to Neutral with a price target of $1.00 (from $6.00).
Analyst Scott Henry cites the disappointing results form the interim Phase 3 review of Tonmya for the downgrade.
For an analyst ratings summary and ratings history on Tonix Pharma click here. For more ratings news on Tonix Pharma click here.
Shares of Tonix Pharma closed at $3.95 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Morgan Stanley Upgrades Telecom Argentina (TEO) to Overweight
- Litchfield Hills Starts NextPlat (NXPL) at Buy
- KB Home (KBH) PT Raised to $56 at Truist Securities
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT Change, Downgrades, Hot DowngradesRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
